9th Annual Risk Management and Pharmacovigilance Summit

26-27 October 2022 | Vienna

In today’s fast changing and unforeseeable times, pharmaceutical companies need to follow a wide range of processes and stick to the majority of regulations, in order to ensure their pharmacovigilance is up to standards. But how to be in charge of the key component of effective drug regulation systems? The answer would be easy, well known as a PV.

Pharmacovigilance is the beating heart of pharmaceutical production. Without it, there would be no way to assess the effectiveness of drugs in comparison to their side effects. Especially today, when the pandemic is having a profound effect on the lives of millions of people around the world and the threat of disease and increasing casualties are destabilising every single industry, it’s important to protect the patients and enable the dissemination of knowledge amongst professionals to minimise the risk of adverse events. Let us see and reveal more what is hidden beyond the “unknown” of drug safety world.

The 9th Annual Risk Management and Pharmacovigilance Summit has been designed to embrace all the current topics and challenges that are important to explore and find the answers on how to embark the patients on the pharmacovigilance ships, what are the advances in structured benefit-risk assessment, what are the effective tools in signal detections, what are types of data available for predictive approaches, how to trust Artificial Intelligence for bias-free identification of risk factors for ADRs and many more. At this 9th Annual Risk Management and Pharmacovigilance conference you will hear 16+ real-life case studies and you have a chance to meet C-level representatives of leading pharma companies that have managed to provide the best safety measures to their patients in recent years.

This interactive pharma meeting will provide you with lessons learned and valuable tips shared by top players in the field. You will also benefit from remarkable networking opportunities due to limited seats of this business event. It is the right place for sharing ideas, getting insights and inspiration, learning from experienced leaders and establishing important business contacts valuable for your next future business path!

Hottest topics that will be discussed this annual

  • How to effectively manage the adverse event data from digital initiatives?
  • What are the recent advances in Benefit-Risk field?
  • How patient safety could be more patient centric?
  • How to handle audits in remote conditions (Covid-19)?
  • The importance of involvement of patients in PV activities

SUMMIT WILL HOST SPEAKERS FROM THE WORLD’S LEADING COMPANIES

Andreas OSANGER

Director - Therapeutic Area Lead Nephrology

CASE STUDY DAY 2

Building PV Partnerships for Drug Product Portfolios

Monika MANSKE

Lead Quality Management and Deputy EEA QPPV

CASE STUDY DAY 2

PV Audit and Inspection Challenges During Pandemic Situation

• Pharmacovigilance System Master File (PSMF)
• Inspection readiness
• Internal PV audits
• Audits by license partner
• How to handle audits in remote situations (COVID-19)
• How will audits be continued after the pandemic?

Stephanie TCHERNY

Global Head of Benefit-Risk Evaluation

CASE STUDY DAY 2

Advances in Structured Benefit-Risk Assessment

This presentation aims to display the recent advances in Benefit-Risk field from new regulatory guidance, changes in BR methods to illustration of growing role of patient experience data into BR evaluation.

• Recent changes in Benefit-Risk regulatory landscape
• Improved use of Patient Experience Data for Benefit-Risk evaluation
• Trends and perspectives for the future in Benefit-Risk methods

Victoria BARTASEK

Senior Associate Director, Global Pharmacovigilance

CASE STUDY DAY 1

How to Effectively Manage the Adverse Event Data from Digital Initiatives?

Lisa STAGI

Drug Safety & Quality Head

CASE STUDY DAY 1

Patient Associations and Patients as Key Players in Pharmacovigilance: Reflections

The importance of proper awareness of patients and more involvement in PV activities is a key topic in the evolution on PV world. I propose to present the experience gained in this area through the work done also with the support of Patient associations.
• PV awareness from Patients
• Opportunities for more involvement of patients and a patient centric approach to PV activities

I really enjoyed the programme and different speakers I had opportunity to hear.

– Head Regulatory Affairs Radiology Medical Devices EMEA, Bayer

We offer to world’s leading companies at our summit

Case Studies

Experience leaders will provide you with lessons learned.

Networking

The chance for market-leading business knowledge networking.

Discussions

All attendees will have a great opportunity to discuss a selection of topics in small groups with their peers.

New Ideas

We are partnering with experienced professionals to provide creative ideas, inspiration, and guidance.

Allan Lloyds Summit mission is to exceed expectations

We are committed to achieving new standards of excellence by providing conference formats that encourages interaction, networking and high class knowledge sharing. With experts, well-supported staff, motivated to deliver quality, Allan Lloyds vision is to be recognized as the global leader in providing high quality business conferences.

What we offer to world’s leading companies

  • Experience-based case studies
  • Round table discussions
  • Impeccable networking opportunities
  • Limited number of seats in the audience ensuring friendly atmosphere
  • No media or press presence

Sponsors

Few photos from our summits

Event programme

Fill your details in the form and we will
send you the whole brochure filled with all details

Your copy of the brochure is prepared.

Inside you will find

  • What keynote speakers will be taking part in the exclusive speaking panel
  • What Case Studies will be discussed by our senior corporate speakers
  • The minute by minute breakdown of the conference